[
  {
    "ts": null,
    "headline": "Merck's Drug Slashes PAH Risk by 76%--FDA Fast-Tracks Game-Changer",
    "summary": "FDA fast-tracks Merck's WINREVAIR after jaw-dropping results in high-risk pulmonary hypertension patients",
    "url": "https://finnhub.io/api/news?id=0c465a32972147f4460654f77e44dc28f27cb920b192ee1eb205712b7af28c58",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751491851,
      "headline": "Merck's Drug Slashes PAH Risk by 76%--FDA Fast-Tracks Game-Changer",
      "id": 135718615,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "FDA fast-tracks Merck's WINREVAIR after jaw-dropping results in high-risk pulmonary hypertension patients",
      "url": "https://finnhub.io/api/news?id=0c465a32972147f4460654f77e44dc28f27cb920b192ee1eb205712b7af28c58"
    }
  },
  {
    "ts": null,
    "headline": "Merck's HPV Vaccine Gardasil Remains Key Driver Ahead of Q2 Results, UBS Says",
    "summary": "Merck's (MRK) human papillomavirus or HPV vaccine Gardasil remains a key driver for the drugmaker, y",
    "url": "https://finnhub.io/api/news?id=d2e3cd10d13235fb2e755c46a61416a4a18505515edd62834e1c30dd1c26ae89",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751483857,
      "headline": "Merck's HPV Vaccine Gardasil Remains Key Driver Ahead of Q2 Results, UBS Says",
      "id": 135718616,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck's (MRK) human papillomavirus or HPV vaccine Gardasil remains a key driver for the drugmaker, y",
      "url": "https://finnhub.io/api/news?id=d2e3cd10d13235fb2e755c46a61416a4a18505515edd62834e1c30dd1c26ae89"
    }
  },
  {
    "ts": null,
    "headline": "Merck (NYSE:MRK) Gains FDA Priority Review For WINREVAIR PAH Treatment sBLA",
    "summary": "Merck (NYSE:MRK) recently announced the FDA's priority review for an sBLA for WINREVAIR™ and results from its ZENITH trial, showcasing significant improvements in pulmonary arterial hypertension treatment. Despite a 6.5% increase in Merck’s share price last month, market dynamics show a correlation rather than a direct causation, as the broader market rose as well. Key events included Merck's inclusion in the Russell 3000 and 1000 Value Indexes and regulatory achievements for treatments like...",
    "url": "https://finnhub.io/api/news?id=10a46c45ab7038163919e531074c7cf3d4207c5fa815d01a37bfe75e93fc96f4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751477896,
      "headline": "Merck (NYSE:MRK) Gains FDA Priority Review For WINREVAIR PAH Treatment sBLA",
      "id": 135718617,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck (NYSE:MRK) recently announced the FDA's priority review for an sBLA for WINREVAIR™ and results from its ZENITH trial, showcasing significant improvements in pulmonary arterial hypertension treatment. Despite a 6.5% increase in Merck’s share price last month, market dynamics show a correlation rather than a direct causation, as the broader market rose as well. Key events included Merck's inclusion in the Russell 3000 and 1000 Value Indexes and regulatory achievements for treatments like...",
      "url": "https://finnhub.io/api/news?id=10a46c45ab7038163919e531074c7cf3d4207c5fa815d01a37bfe75e93fc96f4"
    }
  },
  {
    "ts": null,
    "headline": "July Dog Of The Dow's 'Safer' Buy: Verizon",
    "summary": "Verizon Communications Inc. stands out as the top Dow dividend pick with strong cash flow and value potential. Click for my analysis and why I like VZ.",
    "url": "https://finnhub.io/api/news?id=8925dda184e2b9957f67d5da8f9ed43de30abb890049f9b7f766093e43a0a1fa",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751476862,
      "headline": "July Dog Of The Dow's 'Safer' Buy: Verizon",
      "id": 135716420,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2181800802/image_2181800802.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Verizon Communications Inc. stands out as the top Dow dividend pick with strong cash flow and value potential. Click for my analysis and why I like VZ.",
      "url": "https://finnhub.io/api/news?id=8925dda184e2b9957f67d5da8f9ed43de30abb890049f9b7f766093e43a0a1fa"
    }
  },
  {
    "ts": null,
    "headline": "THQ: Valuation Remains Unappealing Even If Portfolio Is Beaten-Down",
    "summary": "THQ struggles with healthcare sector underperformance and trades at a premium. Read the full report on why THQ's high yield may face challenges.",
    "url": "https://finnhub.io/api/news?id=04c7bf0158dca8563c770c83f1f06a210e91409842a5d6e2d8ce42452ec973e9",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751472824,
      "headline": "THQ: Valuation Remains Unappealing Even If Portfolio Is Beaten-Down",
      "id": 135715852,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2203781634/image_2203781634.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "THQ struggles with healthcare sector underperformance and trades at a premium. Read the full report on why THQ's high yield may face challenges.",
      "url": "https://finnhub.io/api/news?id=04c7bf0158dca8563c770c83f1f06a210e91409842a5d6e2d8ce42452ec973e9"
    }
  },
  {
    "ts": null,
    "headline": "What's Fueling Tempus AI's Explosive Sales Growth?",
    "summary": "TEM's Q1 revenues jump 75.4%, powered by soaring genomics sales, strategic deals and new test launches.",
    "url": "https://finnhub.io/api/news?id=f736289550c7b98015a09c3ec85da18d8dd928b510d65da4e926d08811c71aaf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751458260,
      "headline": "What's Fueling Tempus AI's Explosive Sales Growth?",
      "id": 135711688,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "TEM's Q1 revenues jump 75.4%, powered by soaring genomics sales, strategic deals and new test launches.",
      "url": "https://finnhub.io/api/news?id=f736289550c7b98015a09c3ec85da18d8dd928b510d65da4e926d08811c71aaf"
    }
  },
  {
    "ts": null,
    "headline": "FDA Grants Priority Review for WinrevaIR (sotatercept-csrk) to Update Label Based on Results from Zenith Trial of Merck & Co., Inc",
    "summary": "Merck announced that the U.S. Food and Drug Administration has accepted and granted priority review for a new supplemental Biologics License Application seeking approval to update the U.S. product...",
    "url": "https://finnhub.io/api/news?id=3220ae8f8014d96b9ac78e2eebd8ac209bca8b85f232bb62e664fa276e432d96",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751456253,
      "headline": "FDA Grants Priority Review for WinrevaIR (sotatercept-csrk) to Update Label Based on Results from Zenith Trial of Merck & Co., Inc",
      "id": 135713315,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "Merck announced that the U.S. Food and Drug Administration has accepted and granted priority review for a new supplemental Biologics License Application seeking approval to update the U.S. product...",
      "url": "https://finnhub.io/api/news?id=3220ae8f8014d96b9ac78e2eebd8ac209bca8b85f232bb62e664fa276e432d96"
    }
  },
  {
    "ts": null,
    "headline": "Merck concludes SpringWorks acquisition for $3.4bn",
    "summary": "Merck adds two SpringWorks’ products targeting rare tumours with limited treatment options.",
    "url": "https://finnhub.io/api/news?id=6bd4cb6ae916e461e97a736095499e4852e3641099b0a7e4c1a686d5fb6e811d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751454197,
      "headline": "Merck concludes SpringWorks acquisition for $3.4bn",
      "id": 135710972,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck adds two SpringWorks’ products targeting rare tumours with limited treatment options.",
      "url": "https://finnhub.io/api/news?id=6bd4cb6ae916e461e97a736095499e4852e3641099b0a7e4c1a686d5fb6e811d"
    }
  },
  {
    "ts": null,
    "headline": "FDA Grants Priority Review for WINREVAIR™ (sotatercept-csrk) to Update Label Based on Results From ZENITH Trial",
    "summary": "RAHWAY, N.J., July 02, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted priority review for a new supplemental Biologics License Application (sBLA) seeking approval to update the U.S. product label based on the Phase 3 ZENITH trial for WINREVAIR™ (sotatercept-csrk). In 2024, WINREVAIR was approved for the treatment of adults with pulmonary arterial hypertension (PAH, Group 1 PH",
    "url": "https://finnhub.io/api/news?id=43c262c52ecf8f284b922f3ea3f5cee9048d5712a8487493f9d1c98b687ef748",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751453100,
      "headline": "FDA Grants Priority Review for WINREVAIR™ (sotatercept-csrk) to Update Label Based on Results From ZENITH Trial",
      "id": 135711230,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "RAHWAY, N.J., July 02, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted priority review for a new supplemental Biologics License Application (sBLA) seeking approval to update the U.S. product label based on the Phase 3 ZENITH trial for WINREVAIR™ (sotatercept-csrk). In 2024, WINREVAIR was approved for the treatment of adults with pulmonary arterial hypertension (PAH, Group 1 PH",
      "url": "https://finnhub.io/api/news?id=43c262c52ecf8f284b922f3ea3f5cee9048d5712a8487493f9d1c98b687ef748"
    }
  },
  {
    "ts": null,
    "headline": "Merck: FDA priority review status for Winrevair",
    "summary": "Merck announces that the FDA has granted priority review to its supplemental biologics license application to update the US  labeling for Winrevair in pulmonary arterial hypertension . Merck's...",
    "url": "https://finnhub.io/api/news?id=9a8d0a4d7076690a398dde36a610376816ca71989b73184b0320670a44a7b4cf",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751446753,
      "headline": "Merck: FDA priority review status for Winrevair",
      "id": 135710886,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "Merck announces that the FDA has granted priority review to its supplemental biologics license application to update the US  labeling for Winrevair in pulmonary arterial hypertension . Merck's...",
      "url": "https://finnhub.io/api/news?id=9a8d0a4d7076690a398dde36a610376816ca71989b73184b0320670a44a7b4cf"
    }
  },
  {
    "ts": null,
    "headline": "Can China sustain a surge in oncology drug innovation?",
    "summary": "The country’s trajectory may get a boost from anticipated results of a Keytruda rival’s U.S. trials.",
    "url": "https://finnhub.io/api/news?id=85752762f0ab1763501cefbdd251f02a0b4027f9afc520e236567467befb11a9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751443200,
      "headline": "Can China sustain a surge in oncology drug innovation?",
      "id": 135712962,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "The country’s trajectory may get a boost from anticipated results of a Keytruda rival’s U.S. trials.",
      "url": "https://finnhub.io/api/news?id=85752762f0ab1763501cefbdd251f02a0b4027f9afc520e236567467befb11a9"
    }
  },
  {
    "ts": null,
    "headline": "Summit Therapeutics (SMMT) Rated Buy on Ivonescimab’s Cancer-Fighting Potential",
    "summary": "Summit Therapeutics Inc. (NASDAQ:SMMT) ranks among the 30 stocks expected to beat the market by 20 percentage points this year. Analysts at H.C. Wainwright reaffirmed their Buy rating on Summit Therapeutics Inc. (NASDAQ:SMMT) on June 2, citing a $44 price target. The analysts emphasized how Summit Therapeutics’ medication ivonescimab holds the potential to emerge as […]",
    "url": "https://finnhub.io/api/news?id=12cbe098cf59db99c230155eed20d1ed396eafa5bd16a8f856e1005bab9cf33a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751438852,
      "headline": "Summit Therapeutics (SMMT) Rated Buy on Ivonescimab’s Cancer-Fighting Potential",
      "id": 135710882,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Summit Therapeutics Inc. (NASDAQ:SMMT) ranks among the 30 stocks expected to beat the market by 20 percentage points this year. Analysts at H.C. Wainwright reaffirmed their Buy rating on Summit Therapeutics Inc. (NASDAQ:SMMT) on June 2, citing a $44 price target. The analysts emphasized how Summit Therapeutics’ medication ivonescimab holds the potential to emerge as […]",
      "url": "https://finnhub.io/api/news?id=12cbe098cf59db99c230155eed20d1ed396eafa5bd16a8f856e1005bab9cf33a"
    }
  },
  {
    "ts": null,
    "headline": "China Emerging As Global Biotechnology Player",
    "summary": "China's biotech sector is rapidly advancing due to heavy R&D investment and a push for technological self-sufficiency. See the complete analysis here.",
    "url": "https://finnhub.io/api/news?id=7b01930d39d91b3d2d937b94c926332d805e0cbf1232b074a9fc0a195df32b1a",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751425329,
      "headline": "China Emerging As Global Biotechnology Player",
      "id": 135705670,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2205686978/image_2205686978.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "China's biotech sector is rapidly advancing due to heavy R&D investment and a push for technological self-sufficiency. See the complete analysis here.",
      "url": "https://finnhub.io/api/news?id=7b01930d39d91b3d2d937b94c926332d805e0cbf1232b074a9fc0a195df32b1a"
    }
  }
]